Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14403373 | 1.00 | TACR1 (0.53) | TACR1PDE4BMEN1KMT2ARORC | |
| SCHEMBL1751275 | 1.00 | TACR1 (0.53) | TACR1PDE4BMEN1KMT2ARORC | |
| SCHEMBL4760975 | 1.00 | TACR1 (0.53) | TACR1PDE4BMEN1KMT2ARORC | |
| SCHEMBL951268 | 1.00 | TACR1 (0.53) | TACR1PDE4BMEN1KMT2ARORC | |
| SCHEMBL951494 | 1.00 | TACR1 (0.53) | TACR1PDE4BMEN1KMT2ARORC | |
| SCHEMBL13594769 | 0.91 | TACR1 (0.52) | TACR1PDE4BMEN1KMT2ARORC | |
| SCHEMBL18252871 | 0.91 | TACR1 (0.51) | TACR1PDE4BMEN1KMT2ARORC | |
| SCHEMBL4413164 | 0.91 | PDE4B (0.50) | TACR1PDE4BMEN1KMT2ARORC | |
| SCHEMBL1971427 | 0.91 | PDE4B (0.50) | TACR1PDE4BMEN1KMT2ARORC | |
| SCHEMBL4413170 | 0.91 | PDE4B (0.50) | TACR1PDE4BMEN1KMT2ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004605-B1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-29 | — | — | EP | disclosed |
| EP-2188266-A2 | NOVEL PIPERAZINE AMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009021868-A2 | NOVEL PIPERAZINE AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-19 | — | — | WO | disclosed |
| EP-2004605-A1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113153-A1 | PIPERIDINE DERIVATIVES USEFUL AS SEROTONIN TRANSPORTER INHIBITORS AND NEUROKININ-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| EP-1372653-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7015235-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060035935-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | GOULET MARK T | 2006-02-16 | — | — | US | disclosed |
| EP-1372653-A4 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040097546-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2004-05-20 | — | — | US | disclosed |
| EP-1372653-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002068387-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035935-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | TACR1 587/4885PDE4B 62/4885MEN1 2447/4885 |
| US-20040097546-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | TACR1 587/4885PDE4B 62/4885MEN1 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.